US Supreme Court narrows inducement liability for 'skinny label' generic drugs
By Nick Robertson ( June 4, 2026, 20:04 GMT | Insight) -- The Supreme Court unanimously ruled Thursday that generic drug manufacturer Hikma Pharmaceuticals' FDA-approved skinny label and marketing materials describing its product as equivalent to Amarin Pharma's branded drug were insufficient to plausibly allege induced patent infringement. The ruling narrows the circumstances under which branded drugmakers can pursue inducement claims against generic competitors using skinny labels.The US Supreme Court unanimously held Thursday that a generic drug’s so-called “skinny label” and related marketing statements did not plausibly show the “active steps” required to plead induced infringement of a brand manufacturer's patent, in a significant win for generic drug manufacturers....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.